Issue 38 - The Cancer Letter

Request Cancellation

Subscription Change

This change will be effective immediately and your card will be charged a prorated amount based on your existing subscription level.

OK Cancel

Renew today!

Your subscription has lapsed. Subscribe today to access this content.

SUBSCRIBE NOW

Subscriber content

Log in or subscribe to access The Cancer Letter.

LOGIN SUBSCRIBE NOW

SEARCH DATE

SEARCH TEXT

Cancel

OK

Cancel

OK

Delete Account

Are you sure you want to delete your account? This will erase all of your account data from the site. To delete your account enter your password below

FDA: the development of site-agnostic indications calls for development of sponsor-agnostic diagnostics

The genesis of the first site-agnostic indication

NIH announces immunotherapy consortium with 11 companies to support Cancer Moonshot goals

Lemery: “We saw consistent evidence of the drug's response in multiple tumor types”

Rubin: FDA helped Merck figure out how to channel science into regulatory approval

Nine researchers receive the 2017 NIH Director's New Innovator Award for cancer-related discoveries

Oliver Press, lymphoma physician-scientist, dies at 65

In Brief

Carl June, Sens. Blunt and Casey to receive AACI awards

NCCN Radiation Therapy Compendium provides recommendations for 41 disease sites

The Lung Cancer Research Foundation and Free to Breathe announce Merger

$2.4M grant aids exploration of social media to reduce indoor tanning behavior

FDA awards 15 grants for clinical trials to stimulate product development for rare diseases

Drugs & Targets

FDA grants priority review for Lilly's Verzenio (abemaciclib) for advanced breast cancer

Boehringer Ingelheim's Gilotrif granted Priority Review

Janssen submits NDA for apalutamide in non-metastatic castration-resistant prostate cancer

FDA clears first 7T MRI device

Recent Issues

Renew today!

Subscriber content

Never miss an issue!

Login